Karl Ziegelbauer is currently Chief Scientific Officer of Almirall SA, which he joined in 2021. Prior to that he had been with Bayer AG since 1993, most recently serving as Senior Vice President and Head of Open Innovation & Digital Technologies of the Pharmaceutical Division. Karl’s previous positions at Bayer included: Senior Vice President for the Therapeutic Research Group, Senior Vice President for the Therapeutic Research Group Oncology and Gynecological Therapy, Vice President for Oncology Research, and Vice President for Protein Therapeutics for Bayer Schering Pharma. He also served as Group Leader at Bayer Yakuhin Ltd. in Japan. Prior to joining Bayer, Karl was a Research Fellow at the Max Planck Institute of Biology. Karl holds a PhD in biochemical sciences from the Max Planck Institute of Biology in Germany. He has co-authored more than 60 scientific publications covering topics in basic research as well as drug discovery.